Search Results

advanced-stage subcutaneous mice models reached approximately 250 cubic millimeters in size (day 22 post stopped when tumors of the control group had grown to approximately 1,000 cubic millimeters (day 33 post achieved after ANAVEX 7-1037 had been administered seven times at a statistically significant level (post urgent medical needs like efficacy, drug resistance, side effects, administration and affordability, Research & Business Development Email: info@anavex.com Shareholder & Media Relations Toll-free: 1-866

With these partnerships, ANAVEX is able to outsource parts of the R&D process to drive capital efficiency Alexandre Vamvakides became Chief Scientific Officer and Director, and ANAVEX added a distinguished, medically pharmacology, a M.Sc. in biochemistry and a Ph.D. in molecular pharmacology all from the University of Paris,Medical Cameron Durrant, a medically trained MBA with an entrepreneurial background and major international pharmaceutical and an additional 50 compounds at various early stages of discovery, ANAVEX has one of the industry’s most

results were presented at the Neuroscience 2007 conference in San Diego, California, and are available at https About Alzheimer’s disease Alzheimer’s disease is the most common cause of dementia and is characterized Medications currently available to treat Alzheimer’s disease include acetylcholinesterase inhibitors Both types of medications only treat symptoms of the disease — they do not stop the onset and progression In conclusion, there are very real and unmet medical requirements for drug therapies to treat Alzheimer

Durrant is a medically trained MBA who has a unique entrepreneurial background coupled with major international

results were presented at the 15th Euroconference on Apoptosis (Portoroz, Slovenia), and are available at https reverse the progression of the disease, which have a novel mode of action that could fulfill some of the most urgent medical needs like efficacy, drug resistance, side effects, administration and affordability,

results were presented at the Neuroscience 2007 conference in San Diego, California, and are available at https either intractable or uncontrolled seizures, or have significant adverse side effects due to their medication

as, ratified and approved the company’s 2007 Stock Option Plan unanimously of the 9,975,000 shares cast

Vamvakides has been published over 80 times in highly respected Medical/Scientific journals. Pharmacology, a M.Sc. in Biochemistry and a Ph.D. in Molecular Pharmacology all from the University of Paris, Medical